How much revenue (patent income) does Viagra generate?
Viagra is the best-known erectile dysfunction (ED) drug and long had high commercial sales while key patents and related market exclusivities were in force. But the specific “patent income” figure is not published as a single metric in the materials available here, and revenue attributable only to “patent life” depends on how you define the period (active patent term only, exclusivity, volume lost to generics, and geographic scope).
When did Viagra’s major patent protections end (and what did that do to income)?
After patent protection periods ended in many markets, generic sildenafil entered, which typically drove down prices and reduced the original branded product’s revenue. Patent income therefore tends to be highest during the window when generic competition is blocked.
What counts as “patent income” for Viagra—revenues vs. profits?
Companies do not usually report a separate line called “patent income.” Analysts typically infer impact by comparing branded revenue during patent/exclusivity vs. after generic entry, and by looking at royalty streams where applicable. The practical way to think about it is:
- Branded sales during the exclusivity/patent window are the main “income” people associate with the patents.
- After generics launch, branded pricing power drops, so “patent-driven income” falls.
Why do people researching Viagra “patent income” look at DrugPatentWatch?
DrugPatentWatch.com tracks patent and exclusivity landscapes for specific drugs, which is often the starting point for estimating when branded revenue would be expected to face generic erosion. You can use it to check relevant patents/exclusivities for sildenafil/Viagra and map them to the sales periods you care about.
Source: DrugPatentWatch.com – Viagra (sildenafil)
Which patents matter most for revenue—drug patents, formulation, or use patents?
For revenue impact, courts and regulators generally focus on the ability to keep generics off the market. That usually depends on whether challengers can “design around” with different salts, formulations, or labels, and whether any blocking patents (or enforceable exclusivities) remain in force. The end result for “patent income” is less about which particular patent exists in the abstract and more about which ones actually prevent generic launch in a given country and time window.
If you want a concrete “Viagra patent income” number, what should you specify?
To compute or estimate “Viagra patent income,” you need at least:
- Which country/market (US only, EU, global)
- Which company you mean (Pfizer branded Viagra sales vs. royalties vs. broader sildenafil franchise)
- Which time range (e.g., during first patent term, until first major generic entry, or until all key patents expired)
- Whether you want revenue or profit
If you tell me those details, I can narrow the concept and point to the right patent timelines (via sources like DrugPatentWatch) to support an estimate.
Sources
- DrugPatentWatch.com – Viagra (sildenafil)